1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Depression - Pipeline Review, H2 2020, provides an overview of the Depression (Central Nervous System) pipeline landscape.
Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. Treatment includes antidepressants, mood stabilizers or antipsychotics.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Depression - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Depression (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Depression (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Depression and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 2, 17, 37, 46, 5, 92, 32 and 6 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 14 and 8 molecules, respectively.
Depression (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Depression (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Depression (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Depression (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Depression (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Depression (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Depression (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Depression (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionDepression - Overview
Depression - Therapeutics Development
Depression - Therapeutics Assessment
Depression - Companies Involved in Therapeutics Development
Depression - Drug Profiles
Depression - Dormant Projects
Depression - Discontinued Products
Depression - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Depression, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Depression - Pipeline by Adamed Sp zoo, H2 2020
- Depression - Pipeline by Adare Pharma Solutions, H2 2020
- Depression - Pipeline by Addex Therapeutics Ltd, H2 2020
- Depression - Pipeline by Aision Biotechnologies Inc, H2 2020
- Depression - Pipeline by Alexza Pharmaceuticals Inc, H2 2020
- Depression - Pipeline by Alkermes Plc, H2 2020
- Depression - Pipeline by Allergan Ltd, H2 2020
- Depression - Pipeline by Amorsa Therapeutics Inc, H2 2020
- Depression - Pipeline by Anavex Life Sciences Corp, H2 2020
- Depression - Pipeline by Angelini Group, H2 2020
- Depression - Pipeline by Antheia Inc, H2 2020
- Depression - Pipeline by Asulon Therapeutics Inc, H2 2020
- Depression - Pipeline by Atai Life Sciences AG, H2 2020
- Depression - Pipeline by Athira Pharma Inc, H2 2020
- Depression - Pipeline by Avanir Pharmaceuticals Inc, H2 2020
- Depression - Dormant Projects, H2 2020
- Depression - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Depression, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Molecule Types, H2 2020
- Number of Products by Stage and Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Adamed Sp zoo
- Adare Pharma Solutions
- Addex Therapeutics Ltd
- Aision Biotechnologies Inc
- Alexza Pharmaceuticals Inc
- Alkermes Plc
- Allergan Ltd
- Amorsa Therapeutics Inc
- Anavex Life Sciences Corp
- Angelini Group
- Antheia Inc
- Asulon Therapeutics Inc
- Atai Life Sciences AG
- Athira Pharma Inc
- Avanir Pharmaceuticals Inc
- Avicanna Inc
- Axsome Therapeutics Inc
- Azevan Pharmaceuticals Inc
- Baergic Bio Inc
- Beloteca Inc
- Biohaven Pharmaceutical Holding Company Ltd
- Bionomics Ltd
- BioXcel Therapeutics Inc
- Blackthorn Therapeutics Inc
- Blue Oak Pharmaceuticals Inc
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co
- Calico LLC
- Camino Pharma LLC
- Cellix Bio Pvt Ltd
- Celon Pharma SA
- CGeneTech (Suzhou China) Co Ltd
- Chase Therapeutics Corp
- Chengdu Jinrui Foundation Biotechnology Co Ltd
- Clexio Biosciences Ltd
- Compass Pathways Ltd
- CSPC Pharmaceutical Group Ltd
- CuroNZ Ltd
- Cybin Therapeutics Inc
- Delpor Inc
- Denovo Biopharma LLC
- Douglas Pharmaceuticals Ltd
- Dracen Pharmaceuticals Inc
- Eisai Co Ltd
- Eleusis Ltd
- Eli Lilly and Co
- ES Therapeutics LLC
- Evecxia Inc
- Evotec SE
- Fabre-Kramer Pharmaceuticals Inc
- Gabather AB
- Gilgamesh Pharmaceuticals Inc
- GlaxoSmithKline Plc
- GliaCure Inc
- GNT Pharma Co Ltd
- Guangzhou-Sheng Jian Chi Pharmaceutical Co Ltd
- GW Pharmaceuticals Plc
- H. Lundbeck AS
- HEC Pharm Co Ltd
- HolsboerMaschmeyer NeuroChemie GmbH
- Hua Medicine Shanghai Ltd
- Iltoo Pharma
- Impel NeuroPharma Inc
- Initiator Pharma AS
- Intas Pharmaceuticals Ltd
- IntelGenx Corp
- Intra-Cellular Therapies Inc
- INVENT Pharmaceuticals Inc
- iX Biopharma Ltd
- Jiangsu Gibel Pharmaceutical Co Ltd
- Jiangsu Nhwa Pharmaceutical Co Ltd
- Jina Pharmaceuticals Inc
- Johnson & Johnson
- Kissei Pharmaceutical Co Ltd
- Klaria Pharma Holding AB
- Korea Pharma Co Ltd
- Krenitsky Pharmaceuticals Inc
- Kures Inc
- Lactocore Inc
- Lead Discovery Center GmbH
- Les Laboratoires Servier SAS
- Ligand Pharmaceuticals Inc
- Lixte Biotechnology Holdings Inc
- Luye Pharma Group Ltd
- Lyndra Therapeutics Inc.
- Mapreg SAS
- Marinus Pharmaceuticals Inc
- MD Healthcare Inc
- Medlab Clinical Ltd
- MElkin Pharmaceuticals
- Mental-Heal Ltd
- Meta-IQ ApS
- Methylation Sciences Inc
- miCure Therapeutics Ltd
- Navitor Pharmaceuticals Inc
- Neonc Technologies Inc
- Neurocentrx Pharma Ltd
- Neurocrine Biosciences Inc
- Neurocyte Therapeutics Inc
- Neurolixis Inc
- NeuroNascent Inc
- NeuroPharm Inc
- NeuroRx Inc
- Neurotrope Bioscience Inc
- Nippon Chemiphar Co Ltd
- Novartis AG
- Nubiyota LLC
- Omeros Corp
- Orexigen Therapeutics Inc
- Otsuka Holdings Co Ltd
- Otsuka Pharmaceutical Co Ltd
- Overseas Pharmaceuticals Ltd
- OWP Pharmaceuticals Inc
- Pfizer Inc
- PharmaMax Corp
- Pharmnovo AB
- PharmoRx Therapeutics Inc
- Phytecs
- PNB Vesper Life Science Pvt Ltd
- Praxis Precision Medicines Inc
- Primetime Life Sciences LLC
- Protagenic Therapeutics Inc
- Prous Institute for Biomedical Research SA
- Psy Therapeutics Inc
- PsyBio Therapeutics Inc
- Relmada Therapeutics Inc
- Repurposed Therapeutics Inc
- Reven Pharmaceuticals Inc
- Reviva Pharmaceuticals Inc
- Richter Gedeon Nyrt
- Sage Therapeutics Inc
- Seelos Therapeutics, Inc.
- Seneca Biopharma Inc
- Shanghai SIMR Biotech Co Ltd
- Shanghai Synergy Pharmaceutical Sciences Co Ltd
- Shenox Pharmaceuticals LLC
- Siragen Pharmaceuticals Inc
- Sirtsei Pharmaceuticals Inc
- SK Biopharmaceuticals Co Ltd
- Small Pharma Ltd
- Sosei Heptares
- Sound Pharmaceuticals Inc
- Sumitomo Dainippon Pharma Co Ltd
- Sun Pharma Advanced Research Company Ltd
- Sunovion Pharmaceuticals Inc
- Supernus Pharmaceuticals Inc
- Suven Life Sciences Ltd
- SyneuRx International Corp
- Taisho Pharmaceutical Holdings Co Ltd
- Tasly Holding Group Co Ltd
- Techfields Pharma Co Ltd
- Terran Biosciences Inc
- Tonix Pharmaceuticals Holding Corp
- Trevena Inc
- Vanda Pharmaceuticals Inc
- Viridia Life Sciences
- VistaGen Therapeutics Inc
- Whan In Pharm Co Ltd
- XWPharma
- Yantai YenePharma Co Ltd
- Yungjin Pharm Co Ltd
- Zhejiang Jinhua Conba Bio-pharm Co Ltd
- Zysis Ltd
